clinical trial · NCT07302347
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 20
Malignant NeoplasmCarcinoma, Merkel CellLymphomaPembrolizumab
brief summary
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment
started
Jun 30, 2026
primary completion
Mar 30, 2029
completion
Dec 31, 2029
last updated
Apr 28, 2026
official title
A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol